Kymera Therapeutics (KYMR)
Kymera Therapeutics (NASDAQ: KYMR)
Founded: 2016
Headquarters: Watertown, Massachusetts, USA
Focus Area: Developing innovative small molecule therapies using targeted protein degradation technology
🔬 Key Pipelines / Technologies
| Pipeline | Indication | Clinical Stage | Notes |
|---|---|---|---|
| KT-621 | Atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), etc. | Preclinical | STAT6 protein degrader |
| KT-474 | Immuno-inflammatory diseases | Phase 2 | IRAK4 protein degrader |
| KT-413 | Hematologic malignancies | Phase 1 | IRAKIMiD protein degrader |
| KT-333 | Solid tumors and hematologic malignancies | Phase 1 | STAT3 protein degrader |
- Source: Kymera Therapeutics Pipeline
📅 Recent Major Events
| Date | Event |
|---|---|
| 2025.01.14 | Kymera Therapeutics Outlines Key 2025 Objectives and Strategy |
| 2025.01.07 | Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
💰 Financial Information
| Item | Value |
|---|---|
| Market Capitalization | Approximately $2.2 billion |
| Cash Holdings | Approximately $400 million |
| Annual R&D Spending | Approximately $189 million |
| Operating Loss | Approximately $166 million |
| Number of Employees | Information not available |
| Estimated Cash Runway | Approximately 2.4 years |
Calculation = (Current Assets – Current Liabilities) / Previous Year's Operating Loss
Source: Kymera Therapeutics Financials
🚀 Upcoming Catalysts / Risk Factors
- Upcoming Milestones:
- 2025: Expected Phase 2 results for KT-474
- 2025: Data updates anticipated for KT-413 and KT-333 Phase 1 trials
- Late 2025: Anticipated clinical entry for KT-621
- Risk Factors:
- Pipeline Risk: Potential for clinical trial failures or unforeseen adverse reactions
- Regulatory Changes: Risk of shifts in global regulatory landscapes concerning targeted protein degradation technologies
- Intensifying Competition: Increasing competition in the protein degrader field
- Technical Limitations: Possibility of unforeseen limitations or side effects associated with targeted protein degradation technology
Source: Kymera Therapeutics Pipeline
This content is provided for informational purposes only and does not constitute investment advice.
Investment decisions are the sole responsibility of the individual, and any gains or losses are attributable to the investor.
Updated: 2025-03-25